Bupa, in partnership with Informed Genomics, has launched a “pioneering” genetic test for bladder cancer to its health insurance policyholders for the first time in the UK.
Designed to remove the need for "uncomfortable" hospital testing and promote early diagnosis of the condition, Bupa stated the test could benefit as many as 8,000 policyholders per year who need testing for bladder cancer. The new GALEAS Bladder test detects bladder cancer by picking up genetic markers in urine samples, which can be provided by policyholders from home. Samples are sent for genetic analysis at accredited Informed Genomics laboratories which results shared with the patient's doctor. Test can dietetic genetic mutations associated with 96% of bladder cancers at all stages...
To continue reading this article...
Join COVER for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, key trend analysis and industry insights.
- Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
- Receive breaking news stories straight to your inbox in the daily newsletter.
- Members only access to monthly programme 'The COVER Review'
- Be the first to hear about our CPD accredited events and awards programmes.
